Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 301 in Migraine Prevention
NCT03238781Phase 2Completed
- Sponsor
- Amgen
- Start
- Sep 2017
- Primary completion
- Oct 2018
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of zelminemab in migraine, sponsored by Amgen. Started Sep 2017; status: completed.
02
Drugs
zelminemab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03238781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03238781.